These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 30469048

  • 1. Paclitaxel-betulinic acid hybrid nanosuspensions for enhanced anti-breast cancer activity.
    Wang R, Yang M, Li G, Wang X, Zhang Z, Qiao H, Chen J, Chen Z, Cui X, Li J.
    Colloids Surf B Biointerfaces; 2019 Feb 01; 174():270-279. PubMed ID: 30469048
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78.
    Cai Y, Zheng Y, Gu J, Wang S, Wang N, Yang B, Zhang F, Wang D, Fu W, Wang Z.
    Cell Death Dis; 2018 May 25; 9(6):636. PubMed ID: 29802332
    [Abstract] [Full Text] [Related]

  • 4. Tannic acid-inspired paclitaxel nanoparticles for enhanced anticancer effects in breast cancer cells.
    Chowdhury P, Nagesh PKB, Hatami E, Wagh S, Dan N, Tripathi MK, Khan S, Hafeez BB, Meibohm B, Chauhan SC, Jaggi M, Yallapu MM.
    J Colloid Interface Sci; 2019 Feb 01; 535():133-148. PubMed ID: 30292104
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.
    Diab T, Alkafaas SS, Shalaby TI, Hessien M.
    Anticancer Agents Med Chem; 2020 Feb 01; 20(13):1582-1591. PubMed ID: 32364081
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Enhancing Betulinic Acid Dissolution Rate and Improving Antitumor Activity via Nanosuspension Constructed by Anti-Solvent Technique.
    Li S, Zhang J, Fang Y, Yi J, Lu Z, Chen Y, Guo B.
    Drug Des Devel Ther; 2020 Feb 01; 14():243-256. PubMed ID: 32021108
    [Abstract] [Full Text] [Related]

  • 10. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
    Hu H, Lin Z, He B, Dai W, Wang X, Wang J, Zhang X, Zhang H, Zhang Q.
    J Control Release; 2015 Dec 28; 220(Pt A):189-200. PubMed ID: 26474677
    [Abstract] [Full Text] [Related]

  • 11. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F, Wang X, Xu X, Li M, Zhou J, Wang W.
    Eur J Pharm Sci; 2016 Sep 20; 92():11-21. PubMed ID: 27343697
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Liposome encapsulated albumin-paclitaxel nanoparticle for enhanced antitumor efficacy.
    Ruttala HB, Ko YT.
    Pharm Res; 2015 Mar 20; 32(3):1002-16. PubMed ID: 25213777
    [Abstract] [Full Text] [Related]

  • 14. Impacts of particle size on the cytotoxicity, cellular internalization, pharmacokinetics and biodistribution of betulinic acid nanosuspensions in combined chemotherapy.
    Wang R, Wang X, Jia X, Wang H, Li W, Li J.
    Int J Pharm; 2020 Oct 15; 588():119799. PubMed ID: 32828973
    [Abstract] [Full Text] [Related]

  • 15. Combination of a chemopreventive agent and paclitaxel in CD44-targeted hybrid nanoparticles for breast cancer treatment.
    Tran BN, Nguyen HT, Kim JO, Yong CS, Nguyen CN.
    Arch Pharm Res; 2017 Dec 15; 40(12):1420-1432. PubMed ID: 29027133
    [Abstract] [Full Text] [Related]

  • 16. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
    Bu H, He X, Zhang Z, Yin Q, Yu H, Li Y.
    Int J Pharm; 2014 Aug 25; 471(1-2):206-13. PubMed ID: 24866272
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Biological evaluation of redox-sensitive micelles based on hyaluronic acid-deoxycholic acid conjugates for tumor-specific delivery of paclitaxel.
    Li J, Yin T, Wang L, Yin L, Zhou J, Huo M.
    Int J Pharm; 2015 Apr 10; 483(1-2):38-48. PubMed ID: 25655715
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
    Wang F, Li L, Liu B, Chen Z, Li C.
    Biomed Pharmacother; 2017 Feb 10; 86():595-604. PubMed ID: 28027535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.